Pacific Biosciences Operating Income Over Time
| PACB Stock | USD 2.06 0.20 8.85% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Pacific Biosciences Performance and Pacific Biosciences Correlation. Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. Anticipated expansion of Pacific directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pacific Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (2.13) | Revenue Per Share | Quarterly Revenue Growth (0.04) | Return On Assets | Return On Equity |
Understanding Pacific Biosciences requires distinguishing between market price and book value, where the latter reflects Pacific's accounting equity. The concept of intrinsic value—what Pacific Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Pacific Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Pacific Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pacific Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Pacific Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Pacific Biosciences and related stocks such as Avanos Medical, Orthofix Medical, and Si Bone Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AVNS | 207.9 M | 207.9 M | 226.5 M | 222.9 M | 311.5 M | 154.8 M | (69.4 M) | (16 M) | 34.9 M | (5.4 M) | 70.9 M | 86.8 M | 41.9 M | 65 M | 40 M | 36 M | 34.2 M |
| OFIX | 20.9 M | 32.5 M | 89 M | (5.1 M) | 17.1 M | 9.3 M | 21.1 M | 40.8 M | 30.1 M | (18.8 M) | (6.3 M) | (8.3 M) | (13.3 M) | (139.1 M) | (84.6 M) | (76.2 M) | (72.3 M) |
| SIBN | (10.7 M) | (10.7 M) | (10.7 M) | (5.3 M) | (26.3 M) | (26.4 M) | (17.6 M) | (17.4 M) | (12 M) | (36 M) | (38.6 M) | (51.7 M) | (59.6 M) | (46.9 M) | (35.2 M) | (31.7 M) | (33.3 M) |
| BFLY | (53.1 M) | (53.1 M) | (53.1 M) | (53.1 M) | (53.1 M) | (53.1 M) | (53.1 M) | (53.1 M) | (53.1 M) | (102.3 M) | (161.6 M) | (192.7 M) | (193 M) | (145.6 M) | (74.4 M) | (67 M) | (70.3 M) |
| DRIO | (4 M) | (4 M) | (4 M) | (13.6 M) | (11.4 M) | (7.7 M) | (11.1 M) | (14.4 M) | (17.7 M) | (17.7 M) | (29.9 M) | (76.5 M) | (56.8 M) | (56.2 M) | (57.7 M) | (52 M) | (49.4 M) |
| IOVA | (57.1 K) | (21.2 M) | (8.1 M) | (22.6 M) | (12 M) | (27.9 M) | (53.6 M) | (92.9 M) | (128.3 M) | (206.9 M) | (261.9 M) | (342.7 M) | (398.9 M) | (460.6 M) | (395.3 M) | (355.8 M) | (338 M) |
| IART | (6 M) | 54.9 M | 73.8 M | (3.6 M) | 65.5 M | 79.6 M | 115.3 M | 44.8 M | 111 M | 93.8 M | 151.4 M | 197.2 M | 238.9 M | 111.5 M | 28.4 M | 32.7 M | 31 M |
| FLGT | (990 K) | (990 K) | (990 K) | (990 K) | (990 K) | (5 M) | 919 K | (3.4 M) | (5.1 M) | (428 K) | 290.2 M | 104.3 M | 178.5 M | (195.5 M) | (73.9 M) | (66.5 M) | (63.2 M) |
| DNA | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (137 M) | (1.8 B) | (2.2 B) | (864.4 M) | (559.8 M) | (503.8 M) | (529 M) |
| POM | 125 M | 637 M | 670 M | 668 M | 604 M | 673 M | 3.1 B | 4.3 B | 3.9 B | 4.4 B | (240.4 M) | (79.7 M) | (3.6 M) | (22.2 M) | (25.8 M) | (29.7 M) | (28.2 M) |
Pacific Biosciences and related stocks such as Avanos Medical, Orthofix Medical, and Si Bone Operating Income description
Operating Income is the amount of profit realized from Pacific Biosciences operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Pacific Biosciences of is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Pacific Biosciences of | PACB |
| Classification | Aggressive Defence |
| Business Address | 1305 OBrien Drive, |
| Exchange | NASDAQ Exchange |
USD 2.06
Check out Pacific Biosciences Performance and Pacific Biosciences Correlation. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Pacific Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.